Anika Therapeutics | ANIK - Selling And Administration Expenses


Anika Therapeutics reported $10.01M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Integra LifeSciences USD 178.24M 21.79M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merit Medical Systems USD 110.47M 4.36M Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Smith & Nephew USD 1.42B 65M Dec/2025
Stryker USD 2.15B 17M Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026